Baricitinib Liposomes as a New Approach for the Treatment of Sjögren’s Syndrome
Open Access
- 7 September 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (9) , 1895
Abstract
Sjögren’s syndrome is a chronic systemic autoimmune disease affecting from 0.2 to 3% of the general population. The current treatment for Sjögren’s syndrome is aimed at controlling symptoms such as dry eyes and xerostomia. Systemic therapy with glucocorticoids or immunosuppressants is also used. Baricitinib is an immunosuppressant drug, specifically a Janus kinases 1 and 2 selective inhibitor. We propose ocular liposomal formulations loaded with baricitinib for the management of Sjögren’s syndrome. The novelty of the work relies on the fact that, for the first time, baricitinib is intended to be used for topical delivery. Two liposomal formulations were prepared with different lipids: (i) L-α-phosphatidylcholine (Lα-PC) and (ii) a combination of lipids 1-palmitoyl-2-oleoyl-phosphatidylethanolamine: s1-Palmitoyl-2-oleoyl-sn-glycerol-3-phosphoglycerol (3:1, mol/mol) (POPE:POPG), and they were physicochemically characterized. The in vitro drug release and the ex vivo permeation through corneal and scleral tissues were also assessed. Finally, the tolerance of the formulations on the ocular tissues was evaluated by the HET-CAM technique, as well as through the histological analysis of the cornea and sclera and the cornea transparency. Both liposomes resulted in small, spherical shapes, with suitable physicochemical properties for the ocular administration. Lα-PC led to higher flux, permeation, and retention in the sclera, whereas POPE:POPG led to higher flux and permeation in the cornea. The formulations showed no irritant effects on the chorioallantoic membrane. Additionally, the liposomes did not affect the cornea transparency when they were applied, and the histological analysis did not reveal any structural alteration.Keywords
This publication has 47 references indexed in Scilit:
- Liposome: classification, preparation, and applicationsDiscover Nano, 2013
- Development and Use of Ceramide Nanoliposomes in Cancer2012
- Recent Applications of Liposomes in Ophthalmic Drug DeliveryJournal of Drug Delivery, 2011
- Force Spectroscopy Study of Langmuir−Blodgett Asymmetric Bilayers of Phosphatidylethanolamine and PhosphatidylglycerolThe Journal of Physical Chemistry B, 2010
- Multilamellar liposomes of triamcinolone acetonide: preparation, stability, and characterizationJournal of Liposome Research, 2009
- Stability of fenbendazole suspensions for veterinary useEuropean Journal of Pharmaceutical Sciences, 2008
- Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednateInternational Journal of Pharmaceutics, 2005
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- HET-CAM Test1995
- Clinical biochemistry of tearsSurvey of Ophthalmology, 1981